Pacific Capital Partners Ltd Sells 44,750 Shares of ICU Medical, Inc. $ICUI

Pacific Capital Partners Ltd reduced its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 71.6% in the fourth quarter, HoldingsChannel reports. The firm owned 17,750 shares of the medical instruments supplier’s stock after selling 44,750 shares during the period. ICU Medical makes up approximately 2.7% of Pacific Capital Partners Ltd’s investment portfolio, making the stock its 18th largest position. Pacific Capital Partners Ltd’s holdings in ICU Medical were worth $2,532,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bryce Point Capital LLC purchased a new stake in shares of ICU Medical during the third quarter valued at about $586,000. Inscription Capital LLC grew its position in shares of ICU Medical by 407.9% in the 3rd quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock worth $1,003,000 after buying an additional 6,718 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of ICU Medical by 56.5% during the 3rd quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock worth $34,823,000 after acquiring an additional 104,798 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in ICU Medical during the third quarter valued at approximately $1,096,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in ICU Medical in the third quarter valued at approximately $521,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ICUI shares. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, February 15th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler upped their target price on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Finally, KeyCorp increased their price target on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average price target of $179.33.

ICU Medical Trading Up 1.0%

Shares of ICU Medical stock opened at $125.38 on Tuesday. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $160.29. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of 6,272.14, a PEG ratio of 1.79 and a beta of 0.79. The firm’s 50 day simple moving average is $142.73 and its two-hundred day simple moving average is $138.04.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The company had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. During the same quarter in the previous year, the firm posted $2.11 EPS. The firm’s revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.